Most Read Articles
Stephen Padilla, 08 Apr 2020
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.
Pearl Toh, 14 Nov 2020
Using vadadustat for treating anaemia in patients with chronic kidney disease (CKD) not on dialysis does not come with excess cardiovascular (CV) risk compared with darbepoetin alfa, particularly for those treated to a target Hb range of 10–11 g/dL, according to a prespecified analysis of the PRO2TECT study presented at ASN 2020 Kidney Week.
Audrey Abella, 18 Dec 2020
Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.
Pearl Toh, 17 Dec 2020
A single dose of loratadine/pseudoephedrine combination tablet provides over twice as much nasal relief within an hour compared with fluticasone nasal spray in patients with allergic rhinitis, according to a head-to-head comparison study presented at ACAAI 2020 Meeting.

Comorbidities flag poor outcome on vedolizumab, ustekinumab for IBD

05 Oct 2020

In the treatment of patients with inflammatory bowel disease (IBD), comorbidities, but not patient age, influence the risk of any infection or hospitalizations on either vedolizumab or ustekinumab, a study suggests.

The analysis included 203 vedolizumab‐treated and 207 ustekinumab‐treated IBD patients. A total of 95 patients had one or more comorbidities (Charlson Comorbidity Index [CCI]; 49 and 46 in the respective groups). Sixty-three patients (15.4 percent) were aged 60 years, 140 (34.1 percent) between 40 and 60 years, and 206 (50.2 percent) <40 years. Of those in the oldest age group, 36 patients were treated with vedolizumab and 27 with ustekinumab.

Median treatment duration was 54.0 weeks with vedolizumab and 48.4 weeks with ustekinumab, with median follow‐up time of 104.0 and 52.0 weeks, respectively.

Multivariable logistic regression showed that CCI was significantly associated with the likelihood of any infection (odds ratio [OR], 1.387, 95 percent confidence interval [CI], 1.022–1.883; p=0.036) and hospitalization (OR, 1.586, 95 percent CI, 1.127–2.231; p=0.008) in the vedolizumab group, and also with hospitalization (OR, 1.621, 95 percent CI, 1.034–2.541; p=0.035) in the ustekinumab group.

CCI did not influence treatment efficacy. On the other hand, age was not associated with any outcomes.

The present data indicate that while the efficacy of both drugs is not impaired by the presence of comorbidities or a higher age, comorbidity status assessment should be performed to patients initiating vedolizumab or ustekinumab therapy in order to discuss additional safety risks, according to the researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 08 Apr 2020
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.
Pearl Toh, 14 Nov 2020
Using vadadustat for treating anaemia in patients with chronic kidney disease (CKD) not on dialysis does not come with excess cardiovascular (CV) risk compared with darbepoetin alfa, particularly for those treated to a target Hb range of 10–11 g/dL, according to a prespecified analysis of the PRO2TECT study presented at ASN 2020 Kidney Week.
Audrey Abella, 18 Dec 2020
Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.
Pearl Toh, 17 Dec 2020
A single dose of loratadine/pseudoephedrine combination tablet provides over twice as much nasal relief within an hour compared with fluticasone nasal spray in patients with allergic rhinitis, according to a head-to-head comparison study presented at ACAAI 2020 Meeting.